|Project Title||Principal Investigator||Institution|
|Novel genetic animal models of autism||Powell, Craig||University of Texas Southwestern Medical Center|
|Animal models of autism: Pathogenesis and treatment||Powell, Craig||University of Texas Southwestern Medical Center|
|Neurogenetic model of social behavior heterogeneity in autism spectrum disorders||Platt, Michael||Duke University|
|A non-human primate autism model based on maternal immune activation||Patterson, Paul||University of California, Davis|
|Behavioral, physiological & neuroanatomical consequences of maternal separation||Parr, Lisa||Emory University|
|Behavioral and neural processing of faces and expressions in nonhuman primates||Parr, Lisa||Emory University|
|Dysregulation of PI3K/AKT in social interaction deficits and autism spectrum disorders with macrocephaly||Parada, Luis||University of Texas Southwestern Medical Center|
|Role of L-type calcium channels in hippocampal neuronal network activity||Owen, Scott||Stanford University|
|Systematic analysis of neural circuitry in mouse models of autism||Osten, Pavel||Cold Spring Harbor Laboratory|
|Characterization of a novel mouse model of restricted repetitive behaviors||Moy, Sheryl||University of North Carolina at Chapel Hill|
|Novel models to define the genetic basis of autism||Mills, Alea||Cold Spring Harbor Laboratory|
|A mouse knock-in model for ENGRAILED 2 autism susceptibility||Millonig, James||University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School|
|Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila||McDonald, Thomas||Albert Einstein College of Medicine of Yeshiva University|
|Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders||Malanga, C.J.||University of North Carolina School of Medicine|
|Using Drosophila to model the synaptic function of the autism-linked NHE9||Littleton, J. Troy||Massachusetts Institute of Technology|
|Serotonin, corpus callosum, and autism||Lin, Rick||University of Mississippi Medical Center|
|The genetics of restricted, repetitive behavior: An inbred mouse model||Lewis, Mark||University of Florida|
|Behavioral and physiological consequences of disrupted Met signaling||Levitt, Pat||University of Southern California|
|Neurexin-neuroligin trans-synaptic interaction in learning and memory||Kandel, Eric||Columbia University|
|A comparative developmental connectivity study of face processing||Joseph, Jane||University of Kentucky|
|Neurogenomics in a model for procedural learning||Hilliard, Austin||University of California, Los Angeles|
|A proposal to define cells and circuits impacted in autism spectrum disorders||Heintz, Nathaniel||The Rockefeller University|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|The role of CNTNAP2 in embryonic neural stem cell regulation||Gaiano, Nicholas||Johns Hopkins University School of Medicine|
|Functional genomic dissection of language-related disorders||Fisher, Simon||University of Oxford|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.